Dr. Brad Reinfeld, MD PhD retweeted
Important data from #ESMO2026 in #mCRPC:
🧬 56% of HRR alterations detected by liquid biopsy were predicted to originate from clonal hematopoiesis (CH).
⚠️ Patients with CH-only HRR alterations did not appear to benefit from PARPi monotherapy.
Distinguishing CH from tumor-derived mutations is critical for treatment selection. #ProstateCancer @EAntonarakis @urotoday @PCF_Science @OncoAlert
Dr. Brad Reinfeld, MD PhD retweeted
Now online: Peripheral Blood as the Sole Source of Cancer Neoantigen and Reactive T-cell Discovery doi.org/10.1158/2159-8290.CD…
Dr. Brad Reinfeld, MD PhD retweeted
Presidential symposium 1️⃣!!
Interpath-001: adjuvant INT (intismeram) plus pembro impact in RFS & DMFS for stage II-IV resectable melanoma #ESMO26 @ProfGLongMIA @myESMO #personalizedmedicine – at Madrid, Spain
Dr. Brad Reinfeld, MD PhD retweeted
Now online! A bioavailable GPX4 inhibitor for ferroptosis induction in vivo and tumor suppression dlvr.it/TW2szc
Dr. Brad Reinfeld, MD PhD retweeted
From #ESMO26 & @NEJM
Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer
nejm.org/doi/full/10.1056/NE…
Practice changing data for a terrible disease with hazard ratios that are unequivocal.
Dr. Brad Reinfeld, MD PhD retweeted
Jefferson Street Sound Museum founder Lorenzo Washington dies at 83 tennessean.com/story/news/lo…
Dr. Brad Reinfeld, MD PhD retweeted
🧬 NICHE-2 | Phase II | dMMR colon cancer 🇳🇱
👥 111 pts | Nivo + ipi → surgery
🎯 3-y DFS 100%
📈 5-y OS 100%
🩸 ctDNA clearance 82% pre-op
✅ All ctDNA− post-op
⚠️ Single-arm trial
💡 Remarkable long-term outcomes!
🔗 doi.org/10.1016/S0140-6736(2…
@OncoAlert
Dr. Brad Reinfeld, MD PhD retweeted
🥼Scientists have developed a massively parallel single-cell #CRISPR screening platform in primary human #hematopoietic stem and progenitor cells, capturing known associations and functional annotation of regulator-phenotype relationships.
Read more in @CellStemCell: bit.ly/4dLvplB.
Dr. Brad Reinfeld, MD PhD retweeted
New #JITC article: "Site-specific metabolic and hypoxia-associated profiles in metastatic melanoma" doi.org/10.1136/jitc-2026-01…
Dr. Brad Reinfeld, MD PhD retweeted
Drs. Jennifer Marvin-Peek & Farhad Ravandi summarize the evolving therapeutic landscape of #AML, including current intensive and lower-intensity treatment backbones, approved molecularly targeted therapies, and emerging investigational strategies. 💊
bit.ly/4dI8nMo | @SpringerNature
#OpenAccess #AcuteMyeloidLeukemia
Dr. Brad Reinfeld, MD PhD retweeted
Really excited to share the first comprehensive study of germline DDX41 in MDS undergoing transplantation in @BloodPortfolio .
Grateful to Coleman Lindsley, germline brain Chris Reilly @DanaFarber and whole team from @CIBMTR 🙏❤️
ashpublications.org/blood/ar…
After many years of effort, deliberation, excitement, angst, joy, and Wednesday afternoon lab lunches, our group's first manuscript on cachexia, led by Venise Jan Castillon, Amy Xie, and really our whole lab nature.com/articles/s41591-0… @NatureMedicine
From nature reviews cancer - Mapping the functional dark proteome in cancer
buff.ly/EyN6QCH #bwfcams
Dr. Brad Reinfeld, MD PhD retweeted
New @jclinicalinvest study led by @BraunMDPhD @YaleCancer and super star Dr Madsen : HIF-2α inhibition with belzutifan preserves T-cell effector function in ccRCC—supporting the rationale for combining HIF-2α and PD-1 blockade without compromising T-cell activity.
Reassuring translational evidence!
jci.org/articles/view/204613
Dr. Brad Reinfeld, MD PhD retweeted
A multicenter phase II study of glofitamab plus polatuzumab-R-CHP for patients with diffuse large B-cell lymphoma
ashpublications.org/blood/ar…
Dr. Brad Reinfeld, MD PhD retweeted
There is growing evidence that Nectin-4 expression matters for EV/P response.
We discuss new data linking Nectin-4 expression with treatment outcomes—and what this could mean for biomarker-driven use of EV/P.
Delighted to collaborate with @niklas_kluemper @Markuseckstein3 @DrRosenbergMSK on this @EUplatinum editorial.
Read it here: authors.elsevier.com/c/1ntqg…
Dr. Brad Reinfeld, MD PhD retweeted
T-cell numbers may matter less than their neighborhood.
ICI-responsive melanoma was not simply richer in activated lymphocytes. The distinguishing feature was spatial organization: clonally expanded CD8⁺ tumor-resident T cells, CD4⁺ resident T cells and DC3 dendritic cells assembled into local immune triads found only in responding tumors.
TCF1⁺ progenitor-like resident CD8⁺ cells were also enriched, suggesting these niches may continuously replenish cytotoxic effectors rather than merely host terminally activated cells.
The counterpoint is equally interesting. Resistant tumors still carried strong IFN-γ programs, but alongside exhaustion and an immunosuppressive macrophage state.
So an “inflamed” tumor is not necessarily an effective one. The relevant variable may be whether inflammation is organized into a functional local circuit connecting dendritic cells, helper T cells and renewable cytotoxic T cells.
The study is associative—32 lymph-node metastases included only six ICI responders—and cannot establish that these triads cause response.
But it argues that spatial immune architecture may be a more informative biomarker than T-cell abundance or IFN-γ signaling alone.
#immunotherapy #T_cell #Australia
nature.com/articles/s41467-0…
Dr. Brad Reinfeld, MD PhD retweeted
Tomorrow at #IMS26: MSK myeloma specialist @UrviShahMD will present research on targeting a metabolic-epigenetic axis to improve CAR T therapy in multiple myeloma. @Myeloma_Society
🗓️ Saturday, September 26 | 11 a.m. BT / 6 a.m. ET
Dr. Brad Reinfeld, MD PhD retweeted
New #JITC article: "CT-based deep foundation model for predicting immune checkpoint inhibitor-induced pneumonitis risk in lung cancer" doi.org/10.1136/jitc-2026-01…




































